Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

被引：0
|
作者：
Pietro Ciceri
Susanne Müller
Alison O'Mahony
Oleg Fedorov
Panagis Filippakopoulos
Jeremy P Hunt
Elisabeth A Lasater
Gabriel Pallares
Sarah Picaud
Christopher Wells
Sarah Martin
Lisa M Wodicka
Neil P Shah
Daniel K Treiber
Stefan Knapp
机构：
[1] KINOMEscan Division of DiscoveRx Corporation,Nuffield Department of Clinical Medicine
[2] University of Oxford,Nuffield Department of Clinical Medicine
[3] Structural Genomics Consortium,Nuffield Department of Clinical Medicine
[4] University of Oxford,Division of Hematology/Oncology
[5] Target Discovery Institute (TDI),undefined
[6] BioSeek Division of DiscoveRx Corporation,undefined
[7] University of Oxford,undefined
[8] Ludwig Institute for Cancer Research (LICR),undefined
[9] University of California–San Francisco,undefined
来源：
Nature Chemical Biology | 2014年 / 10卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Kinases are a widely targeted enzyme class in cancer chemotherapy. Several clinically used kinase inhibitors also inhibit bromodomains, epigenetic ‘readers’ of acetylated lysine residues, suggesting that kinase-bromodomain polypharmacology may offer benefits in therapeutic settings.[graphic not available: see fulltext]
引用
收藏
页码：305 / 312
页数：7
相关论文
共 50 条
  • [21] The kinase polypharmacology landscape of clinical PARP inhibitors
    Albert A. Antolin
    Malaka Ameratunga
    Udai Banerji
    Paul A. Clarke
    Paul Workman
    Bissan Al-Lazikani
    Scientific Reports, 10
  • [22] Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase
    Gu, Shuang-Xi
    Xue, Ping
    Ju, Xiu-Lian
    Zhu, Yuan-Yuan
    BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (21) : 5007 - 5016
  • [23] POTENT, RATIONALLY DESIGNED INHIBITORS OF SQUALENE SYNTHASE
    BILLER, SA
    SOFIA, MJ
    ABT, JW
    DELANGE, B
    DICKSON, JK
    FORSTER, C
    GORDON, EM
    HARRITY, T
    MAGNIN, DR
    MARRETTA, J
    RICH, LC
    CIOSEK, CP
    ACS SYMPOSIUM SERIES, 1992, 497 : 65 - 80
  • [24] Inhibition of synucleinopathic seeding by rationally designed inhibitors
    Sangwan, Smriti
    Sahay, Shruti
    Murray, Kevin A.
    Morgan, Sophie
    Guenther, Elizabeth L.
    Jiang, Lin
    Williams, Christopher K.
    Vinters, Harry V.
    Goedert, Michel
    Eisenberg, David S.
    ELIFE, 2020, 9
  • [25] RATIONALLY-DESIGNED INHIBITORS OF PHOSPHOLIPASE-A
    WEI, Y
    GELB, MH
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1988, 195 : 161 - BIOL
  • [26] Rationally designed inhibitors of inosine monophosphate dehydrogenase
    Zhang, HZ
    Rao, K
    Carr, SF
    Papp, E
    Straub, K
    Wu, JC
    Fried, J
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (01) : 4 - 8
  • [27] RATIONALLY DESIGNED INHIBITORS OF PHOSPHOLIPASE-A2
    YUAN, W
    GELB, MH
    BIOCHEMISTRY, 1988, 27 (08) : 3109 - 3109
  • [28] Rationally designed peptide regulators of protein kinase C
    Churchill, Eric N.
    Qvit, Nir
    Mochly-Rosen, Daria
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2009, 20 (01): : 25 - 33
  • [29] Rationally Designed Peptoid Inhibitors of Amyloid-β Oligomerization
    Waugh, Mihyun Lim
    Wolf, Lauren M.
    Moore, Kelly A.
    Servoss, Shannon L.
    Moss, Melissa A.
    CHEMBIOCHEM, 2024, 25 (13)
  • [30] RATIONALLY DESIGNED, POTENT COMPETITIVE INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS
    COREY, EJ
    CASHMAN, JR
    KANTNER, SS
    WRIGHT, SW
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1984, 106 (05) : 1503 - 1504
12345